Cemp, A Mitoxantrone Containing Combination, in the Treatment of Intermediate and High Grade Non-Hodgkin's Lymphoma: an Effective and Non Toxic Therapeutic Alternative for Adult and Elderly Patients: On behalf of Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG)
暂无分享,去创建一个
T. Chisesi | V. Rizzoli | P. Polistena | P. Leoni | L. Salvagno | A. Contu | A. Porcellini | P. Coser | I. Majolino | G. Santini | A. Congiu | G. Zambaldi | L. Indrizzi
[1] T. Chisesi,et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Gómez,et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M Van Glabbeke,et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Gobbi,et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. , 1997, Blood.
[5] G. Longo,et al. A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly. , 1996, Leukemia & lymphoma.
[6] Lipschitz Da. Age-related declines in hematopoietic reserve capacity. , 1995 .
[7] D. Lipschitz. Age-related declines in hematopoietic reserve capacity. , 1995, Seminars in oncology.
[8] F. Mandelli,et al. P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Gail,et al. Increasing incidence of non-Hodgkin's lymphoma. , 1993, Seminars in hematology.
[10] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[11] T. Chisesi. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy. , 1993, Leukemia & lymphoma.
[12] F. d'Amore,et al. Original article: Non-Hodgkin's lymphoma in the elderly A study of 602 patients aged 70 or older from a Danish population-based registry , 1992 .
[13] T. Chisesi,et al. Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG). , 1991, Haematologica.
[14] R A Olshen,et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Monfardini,et al. Management of non-Hodgkin's lymphomas in the elderly. , 1987, Haematologica.
[16] B. Clarkson,et al. Non-Hodgkin's lymphomas: characteristics of long-term survivors following conservative treatment. , 1987, The American journal of medicine.
[17] D. V. Von Hoff,et al. Mitoxantrone: a new anticancer drug with significant clinical activity. , 1986, Annals of internal medicine.
[18] V. Zagonel,et al. Non‐Hodgkin's lymphoma in the elderly. A retrospective clinicopathologic study of 50 patients , 1986, Cancer.
[19] T. Miller,et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Armitage,et al. Aggressive Chemotherapy for Diffuse Histiocytic Lymphoma in the Elderly: Increased Complications with Advancing Age , 1984, Journal of the American Geriatrics Society.
[21] Groopman Je. Biologic and biochemical effects of mitoxantrone. , 1984 .
[22] F. Durr. Biologic and biochemical effects of mitoxantrone. , 1984, Seminars in oncology.
[23] T. Miller,et al. Initial chemotherapy for clinically localized lymphomas of unfavorable histology. , 1983, Blood.
[24] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[25] A. Patchefsky,et al. Non‐hodgkin's lymphomas: A clinicopathologic study of 293 cases , 1974, Cancer.
[26] Z. Fuks,et al. Non‐hodgkin's lymphomas iv. clinicopathologic correlation in 405 cases , 1973, Cancer.
[27] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[28] D.,et al. Regression Models and Life-Tables , 2022 .